We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Addition of Carboplatin to Neoadjuvant Therapy for Triple-negative and HER2-positive Early Breast Cancer (GeparSixto)

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01426880
First Posted: September 1, 2011
Last Update Posted: February 15, 2016
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborators:
TEVA
Roche Pharma AG
GlaxoSmithKline
Information provided by (Responsible Party):
German Breast Group
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Study Completion Date: August 2013
  Primary Completion Date: May 2013 (Final data collection date for primary outcome measure)
Publications: